Active, not recruiting
A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.
NCT05704634
- Conditions
- Lung Cancer, Lung Diseases, Lung Neoplasms, +5 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States